✦ LIBER ✦

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study

✍ Scribed by Carter, Hannah E.; Zannino, Diana; John Simes, R.; Schofield, Deborah J.; Howard, Kirsten; Zalcberg, John R.; Price, Timothy J.; Tebbutt, Niall C.

Book ID: 122202271
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 773 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.09.028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6001 International randomised phase III

6001 International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial

✍ Tebbutt, N.; Gebski, V.; Wilson, K.; Cummins, M.; Robinson, B.; Broad, A.; Cunni 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

A randomised phase III study on capecita

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

✍ Tol, J.; Koopman, M.; Rodenburg, C. J.; Cats, A.; Creemers, G. J.; Schrama, J. G 📂 Article 📅 2008 🏛 Oxford University Press 🌐 English ⚖ 76 KB

471 KRAS, BRAF and PIK3Ca Mutations as P

471 KRAS, BRAF and PIK3Ca Mutations as Predictors of Outcome From Maintenance Therapy with Bevacizumab with or Without Erlotinib After First Line Combination Therapy for Metastatic Colorectal Cancer: Results of the Phase III ACT Trial NCT00598156 Translational Study

✍ Spindler, K.G.; dePont Christensen, R.; Andersen, R.F.; Pallisgaard, N.; Johnson 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB